Treatment of bronchial secretion disorders, especially in acute bronchitis: acute bronchitis and acute episode of chronic bronchopulmonary diseases.

Dosage

Adults and children over 7 years of age: 1 tablet 3 times a day.

Children 2 to 7 years: 1 tablet 2 times a day.

Mode of administration

Oral use.

Allow the tablet to dissolve completely in half a glass of water.

The duration of the treatment will not exceed 8 to 10 days without medical notice.

White round tablet.

Class: Pharmacotherapeutic: MUCOLYTICS, ATC code, R05CB01.

Acetylcysteine ​​is a muco-type muco-type. It exerts its action on the gel phase of the mucus, presumably by breaking the disulfide bridges of the glycoproteins, and thus promotes the expectoration.

Not applicable.

Hypersensitivity to any of the constituents of the product

· Infant (under 2 years of age) (see Warnings and Precautions for Use).
Warnings

The productive coughs, which represent a fundamental element of broncho-pulmonary defense, must be respected.

The association of mucomodifiers, bronchodilators with antitussives and / or substances, drying (atropinic) secretions is irrational

Mucolytics can induce bronchial overcrowding in infants. Indeed, its capacity for draining bronchial mucus is limited, due to the physiological peculiarities of its respiratory tree. They should therefore not be used in infants (see section Contraindications and adverse effects)

Treatment should be re-evaluated in the event of persistence or aggravation of symptoms or pathology.

This medicine contains dextrin (glucose). Its use is inadvisable in patients with glucose and galactose malabsorption syndrome.

This medicinal product contains lactose and is not recommended for use in patients with galactose intolerance, lapp lactase deficiency or malabsorption syndrome, glucose or galactose (hereditary or rare diseases). Br>

This medicinal product contains sorbitol and is not recommended for use in patients with fructose intolerance (rare hereditary disease)

Precautions for use

Caution is advised in patients with peptic ulcers.

This medicinal product contains sodium This medicinal product contains 100 mg sodium per tablet To be taken into account in patients on a strict diet

Not applicable.

Not applicable.

Not applicable.

Pregnancy

Studies in the animal have not demonstrated any teratogenic effect. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected.

Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals in well-conducted studies of two species

In clinical studies, no malformative or fetotoxic effects have occurred to date. However, monitoring of pregnancies exposed to acetylcysteine ​​is insufficient to exclude any risk.

Therefore, the use of acetylcysteine ​​should only be considered during pregnancy if necessary.


There is no data concerning the passage of acetylcysteine ​​in breast milk. However, in view of its low toxicity, the potential risks to the child appear, which are negligible in the treatment of this drug.
As a result, breastfeeding is possible.

· Risk of bronchial over-crowding, especially in the infant and in some patients who are incapable of expectoration, effective (see sections Contraindications and Warnings and Precautions). >

Allergic skin reactions such as pruritus, erythematous rash, urticaria and angioedema

· Possibility of phenomena, intestinal digestive (gastralgia, nausea, diarrhea).

It is then advisable to reduce the dose.

Treatment of bronchial secretion disorders, especially in acute bronchitis: acute bronchitis and acute episode of chronic bronchopulmonary diseases.